A director at Abbvie Inc sold 21,082 shares at 176.300USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Moody's Investors Service ("Moody's") affirmed the ratings of AbbVie Inc. ("AbbVie") including the A3 senior unsecured notes, issuer rating and the Prime-2 senior unsecured commercial paper ratings. The outlook is maintained at stable. These actions follow the announcement that AbbVie will acquire C...
Moody's Investors Service commented that AbbVie Inc.'s announcement that it will acquire ImmunoGen, Inc. for approximately $10.1 billon will enhance its oncology franchise by adding the approved drug Elahere to AbbVie's portfolio. The acquisition also brings oncology pipeline opportunities including...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Moody's Investors Service (Moody's) upgraded the senior unsecured long-term ratings of AbbVie Inc. (AbbVie) to A3 from Baa1. At the same time, Moody's affirmed AbbVie's Prime-2 short-term commercial paper rating. Following these actions, the outlook is stable. "The rating upgrade results from ongo...
n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-tShort Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report...
Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...
GREATER CHINA Sector Commodities: Hawkish Fed stance weighing on metal prices; slower-than-expected downstream demand recovery. Update Link REIT (823 HK/BUY/HK$54.75/Target: HK$61.71): Rights issue for lower gearing and stronger position for investment opportunities. Minth Group (425 HK/BUY/HK$21.55/Target: HK$30.00): Recovery on easing of chip shortage, reopening of China, and new businesses. Maintain BUY. Target price: HK$30.00. INDONESIA Results Indosat (ISAT IJ/BUY/Rp6,175/Target: Rp8,000):...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.